Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects
Jani, Rajendra H., Kansagra, Kevinkumar, Jain, Mukul R., Patel, HarilalVolume:
33
Language:
english
Journal:
Clinical Drug Investigation
DOI:
10.1007/s40261-013-0128-3
Date:
November, 2013
File:
PDF, 582 KB
english, 2013